Stay updated on MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The changes are limited to formatting and layout without any alterations to core study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T18:36:59.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    33 days ago
    Change Detected
    Summary
    Added a government-status notice and updated version to v3.2.0; removed the previous version tag v3.1.0.
    Difference
    3%
    Check dated 2025-10-06T04:26:03.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    The page now shows revision v3.1.0, replacing v3.0.2. This is a version update with no other content changes.
    Difference
    0.1%
    Check dated 2025-09-29T00:58:28.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.
    Difference
    0.2%
    Check dated 2025-09-14T18:42:04.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version, v3.0.1, indicating a recent revision. The previous version, v3.0.0, has been removed from the page.
    Difference
    0.2%
    Check dated 2025-09-07T13:03:05.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has updated its facility name and location details, while also adding new drug information related to skin and connective tissue diseases, including pembrolizumab, dabrafenib, and trametinib. Several outdated dates and references to previous genetic disease resources have been removed.
    Difference
    3%
    Check dated 2025-08-31T04:28:30.000Z thumbnail image

Stay in the know with updates to MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.